GC Cell dosed its first patient with relapsed or refractory NK/T-cell lymphoma in a Phase Ib trial of GCC2005, a fourth-generation allogeneic CD5-targeted CAR-NK cell therapy. The company wrapped up dose escalation in Phase 1a and moved to Phase 1b in October 2026. This new stage zeroes in on dosing regimens and aims to lock in the recommended Phase 2 dose. Seoul Economic Daily reported these milestones as the company tries to speed up development.
Meanwhile, atezolizumab showed lasting responses in relapsed or refractory extranodal NK/T-cell lymphoma during the Phase II NCCH1903/ATTACK trial. PD-L1 biomarkers are now under the microscope as possible predictors of response. Peking University Cancer Hospital & Institute kicked off a Phase II study pairing dexamethasone, azacitidine, pegaspargase, and tislelizumab with radiotherapy for Stage I/II extranodal NK/T-cell lymphoma. The focus: efficacy and safety.
GC Cell plans to expand the number of clinical research centers in South Korea to six in order to accelerate the development of GCC2005.
Competition is fierce. ImmunityBio and Five Prime Therapeutics are pushing targeted approaches alongside Innate Pharma, Nektar Therapeutics, Cantargia, CureTech, Dynavax, Cellid Company, Kiadis Pharma, Multimmune GmbH, CytoVac, XNK Therapeutics, NantKwest, Green Cross Corporation, HiberCell, Bristol-Myers Squibb, Affimed Therapeutics AG, Wugen, Abivax, Glycostem Therapeutics (IPD Therapeutic), Synimmune, GT Biopharma, Bellicum Pharmaceuticals, Asclepius Technology Company Group, PersonGen BioTherapeutics (Suzhou), Chongqing Sidemu Biotechnology, Artiva Biotherapeutics, NKMax, Acepodia, Allife Medical Science and Technology, Bright Path Biotherapeutics, and Kuur Therapeutics (Formerly Cell Medica).
Velcade and Brincidofovir stand out among the most promising therapies. AVM0703 and Busulfan are also in the mix, each with a distinct mechanism. The field is split between small molecules and antibodies, as well as CAR-NK cell and gene therapies. This range reflects the tangled biology of NK cells and the urgent demand for better options.
NK cell immunotherapy taps into the innate immune system’s ability to attack tumors and infected cells. Some strategies activate a patient’s own NK cells with stimulants. Others transfer engineered NK cells or use chimeric antigen receptors. Hematopoietic cancers have seen the most progress so far. The current pipeline tests both single-agent and combination regimens, with delivery routes including intravenous and subcutaneous injections, plus intratumoral administration.
GC Cell’s Phase 1b trial of GCC2005 targets patients who have relapsed after or failed standard therapies. Safety and tolerability are the main endpoints, according to Chosun Daily. The company plans to enroll more patients at the optimal dose to build a stronger safety and efficacy case for a future global registration push. For more on CAR-NK clinical progress, see the reported earlier dosing of the first patient in GC Cell’s Phase 1b trial.
The GCC2005 program remains in the early stages of clinical development, with Phase 1b primarily designed to optimize dosing and regimen rather than to confirm efficacy for registration. No independent data confirm regulatory approval, completion of Phase 1b, or advancement to Phase 2 as of October 2026; only the initiation of Phase 1b and first patient dosing have been reported.
Deals and partnerships are everywhere. Companies are splitting their bets between mono and combination therapies, with candidates sorted by stage, delivery route, and molecule type. The pipeline includes both active and shelved projects, a sign of the high failure rate and scientific hurdles in NK cell therapy.
Pipeline assessment stretches from discovery to Phase III. Products are grouped by how they’re given—intravenous, subcutaneous, or intratumoral—and by molecule type, from small molecules to antibodies, CAR-NK cell therapies, gene therapies, and vaccines. Development spans North America, Europe, and Asia, with clinical sites and companies scattered across these regions.
Advanced cell engineering and biomarker-driven patient selection are now shaping the field. Combination regimens are gaining ground. The next two years will show whether this crowded pipeline can produce therapies that move the needle for patients or if the complexity of NK cell biology will keep tripping up drug developers.
